BTIG downgraded Zimmer Biomet from Buy to Neutral due to limited upside potential and a challenging fiscal 2025, where shares fell 14.8%. New products failed to boost growth significantly, and key initiatives like autonomous robotics are not expected to impact the stock until late 2027 or 2028. BTIG also noted a limited product cycle and salesforce changes in 2026, making strong outperformance unlikely despite ongoing efforts. The current valuation at about 10.5 times earnings reflects these concerns.
Zimmer Biomet has appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai brings nearly 30 years of leadership experience in the medical technology sector, including senior roles at Alcon and GE Healthcare. He re...
Zimmer Biomet Holdings announced its second quarter 2026 earnings conference call will be held on August 5 at 8:30 a.m. ET, with a news release detailing results available earlier that day. The call will be webcast live and available for replay on th...
